How effective is Ocrelizumab?

Ocrelizumab is a treatment for multiple sclerosis (MS), a chronic inflammatory disease that affects the central nervous system, often causing symptoms such as muscle weakness, difficulty walking, and visual impairment. Orelizumab is used primarily in two categories of patients: adults with relapsing multiple sclerosis (RMS), who experience flare-ups of symptoms (relapses) followed by milder or asymptomatic stages; and adults with primary progressive multiple sclerosis (PPMS), whose symptoms gradually worsen over time.

The active ingredient of ocrelizumabOcrelizumab is a monoclonal antibody that specifically targets a target labeled CD20 on the surface of white blood cells. These B cells play an important role in the pathogenesis of multiple sclerosis, causing inflammation and damage by attacking the myelin sheath surrounding nerves. Orelizumabby targeting these B cells and reducing their activity, thereby alleviating the patient's symptoms or slowing the progression of the disease.

Clinical study results show that ocrelizumab shows significant efficacy in reducing the number of relapses. A study of 1,656 patients with relapsing multiple sclerosis showed that the average number of relapses per year for patients treated with ocrelizumab was 0.16, compared with 0.29 for patients treated with interferon beta-1a. The relapse rate of the former was almost half that of the latter. Additionally, another study of 732 patients with primary progressive multiple sclerosis had similarly positive results. The study found that 30% of patients taking ocrelizumab had worsening symptoms lasting 12 weeks or longer, compared with 34% of patients taking placebo.

In summary, ocrelizumab has shown good results in the treatment of patients with multiple sclerosis, especially the relapsing and primary progressive forms. By targeting B cells, Orelizumab not only effectively reduces the recurrence rate of the disease, but also significantly delays the progression of symptoms, providing a new treatment option for patients with multiple sclerosis.

Reference materials:https://www.ocrevus.com/